Pros and cons of using interleukin-2 receptor antibodies in liver transplant recipients.
Hirose
Ryutaro
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D011993:Recombinant Fusion Proteins; D012008:Recurrence
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab